Locations

Michigan

While mesothelioma is a problem in all states, the specific incident rate for Michigan is 1.1 / 100,000. This is below the average rate of 1.1 / 100,000. Click on the tabs below to find mesothelioma and asbestos research in MI, recent MI mesothelioma-related court cases, mesothelioma specialists in MI and potential asbestos hotspots in Michigan.

Michigan Mesothelioma Info

By clicking on the above tabs, you will find information on mesothelioma specific to the state of Michigan

Michigan Research and Clinical Trials

This is a partial list of scientific or medical grants in your state for research into mesothelioma and related illnesses.

Michigan Doctors and Hospitals

This is a partial list of hospitals and physicians that reportedly treat mesothelioma patients in your state.

Michigan Cases

This is a partial list of relevant court cases on mesothelioma in your state.

Disclaimer: Inclusion on this directory does not constitute endorsement by Cancer Monthly, Inc. All physicians who appear in this section do so based on their own expression of interest in the fields of mesothelioma treatment. Cancer Monthly, Inc. has not verified the competence, professional credentials, business practices or validity of the expressed interests of these physicians. Cancer Monthly makes no recommendation of any physician on this list and makes no suggestion that any such physician will cure or prevent any disease. Those consulting a physician on this list should approach the consultation exactly as they would with any other unknown physician.

Research

Abstract: During the first 6 years of this study, telephone interviews have been completed with over 17,000 subjects. Lifetime cigarette smoking histories and occupational histories provide data for assessing workplace risk for eleven cancer sites: lung and bronchus, urinary bladder, colon, rectum, stomach, esophagus, mesothelioma, eye, salivary glands, liver, and melanoma of the skin. A primary objective of this study is to determine occupational cancer risks among blacks and women. Little is known about such risks among women or blacks because nearly all research in this area includes only white men. Other specific aims of this study include investigation of occupational cancer risks among persons who never smoked cigarettes; assessing whether cancer occurs at a younger age than expected in conjunction with occupational risks and determination of occupational cancer risks wig& predominant local industries, such as automobile manufacturing, construction, primary ferrous metals manufacturing, machinery manufacturing, and food processing. Detailed work histories, tobacco use histories, health history, and demographics have been obtained by telephone interview. By the end of the current grant period interviews will be completed with 14,900 cancer cases and 3,366 population referents. Cancer cases were selected from a population-based cancer registry; population referents were selected by random digit dialing. The proposed renewal is for completion of data analysis. The long-term objectives of this study are to develop new hypotheses about occupational cancer risks, provide evidence to support previous suggestions of occupational cancer risk, and ultimately to prevent cancers resulting from workplace exposures. 

Tags: Cancer Information System, Cancer Risk, Environment Related Neoplasm /cancer, Health Survey, Neoplasm /cancer Epidemiology, Occupational Hazard, Tobacco Abuse Agriculture Worker, Bladder Neoplasm, Caucasian, Esophagus Neoplasm, Eye Neoplasm, Female, Food Processing /preparation, Hospital Personnel, Human Age, Human Mortality, Industrial Medicine, Industry, Liver Neoplasm, Lung Neoplasm, Melanoma, Mesothelioma, Military Personnel, Negroid, Rectum Neoplasm, Salivary Gland Neoplasm, Stomach Neoplasm Adult Human (21+), Human Clinical Subject, Interview, Statistics /biometry 

  • Followup Grant: 5R01OH002067-09

Abstract: DESCRIPTION: (Applicant’s Abstract) One in six people will die of cancer. the systemic nature, recall ability and exquisite specificity of the immune system makes immunotherapy an attractive prospect for cancer treatment. Hepatocellular carcinoma, cervical carcinoma, various leukemias and lymphomas all have proposed viral etiologies. Viral encoded tumor specific antigens make viral associated tumors strong candidates for immunotherapy. Recent studies have described the presence of simian virus 40 (SV40)-like gene sequences and proteins (specifically the large tumor antigen: SV40 Tag) in human osteosarcomas, glioblastomas, ependymomas and malignant pleural mesotheliomas (MPM), demonstrating SV40 association with certain human malignancies. To facilitate the development of human clinical protocols for the immunotherapy of SV40 associated human malignancies, the proposed study will employ an SV40 murine tumor system to evaluate the efficacy of CTL transfer therapies and peptide based vaccines designed to target an immune response to SV40 Tag expressing tumors in vivo. Briefly, SV40 Tag specific CTL will be generated by immunization of Balb/c mice with SV40 Tag gene constructs and the epitope specificity determined by using selected H-2d restricted synthetic peptides representing potential CTL epitopes on SV40 Tag. These CTL will be utilized to examine the ability of adoptively transferred T cells to protect against tumor challenge in syngeneic mice. Further, selected synthetic peptides will be examined for the ability to actively induce protective tumor immunity in vivo. Completion of this study will provide valuable information on the active induction of tumor destructive immunity involving SV40 Tag-epitope specific CTL in vivo. Moreover, the information generated using the murine SV40 tumor model will expedite the development of reagents and clinical trials designed to examine SV40 Tag specific immunotherapies for SV40 associated human malignancies. 

Tags: Cytotoxic T Lymphocyte, Neoplasm /cancer Immunology, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Vaccine, Nonhuman Therapy Evaluation, Simian Virus 40, Tumor Antigen Mhc Class I Antigen, Astrocytoma, Disease Model, Drug Screening /evaluation, Ependymoma, Immunogenetics, Mesothelioma, Neoplastic Cell, Neoplastic Transformation, Osteosarcoma, Synthetic Peptide, Virus Antigen, Virus Genetics, Virus Protein, Virus Related Neoplasm /cancer Active Immunization, Laboratory Mouse 

  • Followup Grant: 5R29CA077351-02

Abstract: Wayne State University (WSU) has been an active institutional member of the Southwest Oncology Group for over 20 years. Over these years, our faculty has played an important role in support of SWOG, by providing leadership in the administrative and scientific functions of SWOG, and also by meeting and often exceeding patient accrual goals in a continuous and consistent manner. Thus, WSU has remained in the first quartile of institution’s performance evaluation conducted by SWOG in each of the last five years. The clinical research program in cancer at WSU has been organized along the lines of multidisciplinary disease oriented sites and in a manner which resembles the organ committee orientation of SWOG. Thus, our faculty representation in scientific SWOG committees is constituted by individuals with expertise and commitment towards those areas of research. Accordingly, the translation of ideas into SWOG studies as well as the incorporation of SWOG studies and those of NCI designated high priority trials into WSU treatment priorities get facilitated. The SWOG membership in WSU and the diversity of disciplinary involvement by our faculty has continued to grow over the years. To date, 72 WSU members are currently serving on 104 committees. Similarly, 51 SWOG studies list a WSU member as a study chairman or as study coordinator since the last competing application was submitted. Dr. Laurence Baker, Co-Principal Investigator of this application, will continue to provide administrative and scientific assistance to SWOG as the Associate Chairman of the Group. He will assist the new Principal Investigator, Dr. Manuel Valdivieso, in maintaining the prominence of WSU as a SWOG member institution. 

Tags: Combination Antineoplastic Therapy, Combination Chemotherapy, Neoplasm /cancer Chemotherapy, Neoplasm /cancer Radiation Therapy, Neoplasm /cancer Surgery Bacillus Calmette Guerin Vaccine, Acute Leukemia, Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Antineoplastic, Bladder Neoplasm, Bleomycin, Bone Neoplasm, Breast Neoplasm, Cervix Neoplasm, Cis Platinum Compound, Clinical Trial, Colony Stimulating Factor, Colorectal Neoplasm, Cooperative Study, Cyclophosphamide, Cytosine Arabinoside, Dacarbazine, Doxorubicin, Esophagus Neoplasm, Etoposide, Fluorouracil, Gastrointestinal Neoplasm, Germ Cell Neoplasm, Guanine Analog, Head /neck Neoplasm, Human Therapy Evaluation, Ifosfamide, Interferon Alpha, Interleukin 2, Interleukin 3, Leuprolide, Lung Neoplasm, Lymphoma, Melanoma, Melphalan, Mesothelioma, Metastasis, Mitomycin C, Multiple Myeloma, Nasopharyngeal Neoplasm, Neoplasm /cancer Immunotherapy, Neoplasm /cancer Remission /regression, Nonhodgkin’s Lymphoma, Osteosarcoma, Ovary Neoplasm, Pleural Neoplasm, Prednisone, Prostate Neoplasm, Renal Cell Carcinoma, Sarcoma, Squamous Cell Carcinoma, Tamoxifen, Thorax Neoplasm, Transitional Cell Carcinoma, Uterus Neoplasm, Vincristine Flow Cytometry, Human Subject 

  • Followup Grant: 2U10CA014028-20
  • Followup Grant: 5U10CA014028-21
  • Followup Grant: 5U10CA014028-22

Abstract: Drug resistance is a major cause for failure of cancer chemotherapy in refractory disease. Human solid tumor cells may be intrinsically resistant or may acquire resistance after chemotherapy. Drug resistance is multifactorial and efflux plays a major part in resistance to a variety of natural products used in cancer treatment. Anthracycline, doxorubicin is an important antibiotic used in treatment of a variety of human malignancies. Rapid cellular efflux of doxorubicin has been demonstrated in drug resistant tumor cells. Several relatively non-toxic drugs have been shown to block efflux in vitro and enhance chemosensitivity. Verapamil, cyclosporin and trifluoperazine have been used in vivo with the intent to enhance drug retention and clinical response of refractory tumors. Our earlier studies have shown that prochlorperazine is a potent inhibitor of doxorubicin efflux in human solid tumor cells which are insensitive to efflux blocking action of verapamil. We have completed a phase I trial to determine the maximum. tolerated dose of prochlorperazine in vivo. In cells retrieved from patients on this protocol, significantly enhanced retention of doxorubicin was demonstrated and clinical responses were seen in no-small cell lung cancer and mesotheliomas. In the current project, we proposed to carry out a phase II study combining administration of doxorubicin followed by 2 hr infusion of prochlorperazine. We will also study markers and mechanisms of doxorubicin resistance in tumor cells and cell lines established from patients during the course of therapy on these protocols. Pharmacokinetic and pharmacological data will be collected to identify parameters which may correlate with positive response to efflux blocking. 


Tags: Antineoplastic Antibiotic, Combination Chemotherapy, Doxorubicin, Multidrug Resistance, Neoplasm /cancer Chemotherapy P Glycoprotein, Active Transport, Carcinoma, Combination Antineoplastic Therapy, Drug Tolerance, Gene Expression, Mesothelioma, Pharmacokinetics, Prochlorperazine, Small Cell Carcinoma Of Lung Tissue /cell Culture

Abstract: There is no text on file for this abstract. 


Tags: Respiratory Neoplasms, Lung Neoplasms, Silicates, Asbestos Body Cavities, Pleural Cavity, Body Cavities, Serosa, Neoplastic Transformation, Carcinogenesis, Occupational Health, Occupational Hazards, Optics, Microscopy, Electron*, Respiratory Disorders, Pneumoconiosis, Safety And Occupational Health Study Section Chemistry, Analytical Methods, Spectrometry, Atomic Absorption*, Chemistry, Analytical Methods, Spectrometry, Emission*, Chemistry, Analytical Methods, X-ray Structure Analysis*, Mammals, Lagomorphs*, Mammals, Mice*, Mammals, Rats*, Mammals, Rodents, Gerbils*, Mammals, Rodents, Guinea Pigs*, Mammals, Rodents, Hamsters*

Abstract: There is no text on file for this abstract. 


Tags: Respiratory Neoplasms, Lung Neoplasms, Silicates, Asbestos Body Cavities, Pleural Cavity, Body Cavities, Serosa, Neoplastic Transformation, Carcinogenesis, Occupational Health, Occupational Hazards, Optics, Microscopy, Electron*, Respiratory Disorders, Pneumoconiosis, Safety And Occupational Health Study Section Chemistry, Analytical Methods, Spectrometry, Atomic Absorption*, Chemistry, Analytical Methods, Spectrometry, Emission*, Chemistry, Analytical Methods, X-ray Structure Analysis*, Mammals, Lagomorphs*, Mammals, Mice*, Mammals, Rats*, Mammals, Rodents, Gerbils*, Mammals, Rodents, Guinea Pigs*, Mammals, Rodents, Hamsters*

Clinical Trials

Condition: Malignant Mesothelioma
Intervention: Drug: carboplatin;   Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: pazopanib hydrochloride;   Other: laboratory biomarker analysis
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: erlotinib hydrochloride
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: cediranib maleate
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: cisplatin;   Drug: gemcitabine hydrochloride
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: everolimus
More Information

Condition: Malignant Mesothelioma;   Pulmonary Complications
Intervention: Genetic: microarray analysis;   Genetic: protein expression analysis;   Genetic: proteomic profiling;   Other: laboratory biomarker analysis
More Informati

Condition: Malignant Mesothelioma
Intervention: Drug: epirubicin hydrochloride;   Drug: gemcitabine hydrochloride
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: doxorubicin hydrochloride;   Drug: ranpirnase
More Information

Condition: Malignant Pleural Mesothelioma;   MPM;   Solid Tumors
Intervention: Drug: pemetrexed, cisplatin and CBP501;   Drug: pemetrexed and cisplatin
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: dasatinib;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: vatalanib
More Information

Condition: Malignant Mesothelioma
Intervention: Drug: cediranib maleate;   Other: laboratory biomarker analysis
More Information

Condition: Mesothelioma
Intervention: Drug: Pemetrexed;   Drug: Gemcitabine
More Information

Condition: Mesothelioma;   Lung Cancer
Intervention: Drug: Comparator: Suberoylanilide Hydroxamic Acid (Vorinostat, MK0683);   Drug: Comparator: Placebo
More Information

Condition: Malignant Mesothelioma
Intervention: Biological: bevacizumab;   Drug: cisplatin;   Drug: gemcitabine hydrochloride
More Information

Condition: Pleural Neoplasms
Intervention: Drug: pemetrexed;   Drug: cisplatin
More Information

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
More Information

Hospital and Cancer Centers

Barbara Ann Karmanos Cancer Institute
110 East Warren Avenue
Detroit, MI
313.745.8746 

McAuley Cancer Care Bldg. Room C139
5301 Huron River Dr.
Ypsilanti, MI
734.712.1000

Cases

Miller v. Ford Motor Co. (In re Certified Question)
No. 131517, SUPREME COURT OF MICHIGAN, May 10, 2007, Argued, July 25, 2007, Decided, July 25, 2007, Filed

Chapin v. A & L Parts, Inc.
SC: 133410, SUPREME COURT OF MICHIGAN, June 22, 2007, Decided

Chapin v. A & L Parts, Inc.
SC: 133412, SUPREME COURT OF MICHIGAN, June 22, 2007, Decided

Chapin v. A & L Parts, Inc.
SC: 133178, SUPREME COURT OF MICHIGAN, June 22, 2007, Decided

Grand Trunk W. R.R. v. 37th Circuit Court Judge
No. 273411, COURT OF APPEALS OF MICHIGAN, September 11, 2008, Decided

Chapin v. A & L Parts, Inc.
No. 257917 , COURT OF APPEALS OF MICHIGAN, January 11, 2007, Submitted , January 30, 2007, Decided

Creech v. W.A. Foote Mem. Hosp.
No. 237437, No. 237438, No. 237439, No. 237440, No. 237441, No. 237442, No. 237443, No. 237444, No. 237445, No. 237446, COURT OF APPEALS OF MICHIGAN, June 8, 2004, Decided

SIGRID BREAK, Personal Representative of the Estate of John Break v. OWENS-CORNING FIBERGLAS CORP.
No. 203289, COURT OF APPEALS OF MICHIGAN, May 7, 1999, Decided

Lawyers

If you would like information on how to see the published ratings for different mesothelioma lawyers and law firms, please fill-in the form below:

Name (required)

State (required)

Your Email (required)

Phone

Navigation